68Ga-FAPI PET/CT in Malignant Tumors

Launched by ZHONGNAN HOSPITAL · Aug 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called 68Ga-FAPI PET/CT to help doctors see and understand certain types of cancer better. The focus is on a special protein called fibroblast activation protein (FAP), which is found in the tissue surrounding tumors. By using a specially designed probe that targets FAP, researchers hope to improve how we can visualize and diagnose various malignant tumors, especially in the gastrointestinal tract. Previous studies have shown promising results, but this trial aims to gather more comprehensive data with a larger group of patients.

To be eligible for this trial, participants should be between the ages of 18 and 80 and have either suspected or confirmed malignant tumors. They must be willing to sign a consent form to participate. However, women who are pregnant or planning to become pregnant within six months, as well as those who have allergies to multiple drugs, cannot join. Participants will undergo imaging tests that are designed to be safe and may help improve cancer diagnosis. If you or someone you know is interested, it’s a great opportunity to contribute to important cancer research!

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Volunteering to participate in clinical trial and sign an informed consent form Patients with suspected or confirmed malignant tumor
• Exclusion Criteria:
• • Female patients plan to become pregnant within 6 months Pregnant and lactating women Patients are allergic to multiple drugs including test drug Patients have participated in other clinical trials in the past one month